Science
Unlocking Anti-Cancer Immunity
Our immune system is powerful yet struggles to recognize and attack cancer cells.
ME Therapeutics is working at this frontier of immuno-oncology to bring life-saving treatments to cancer patients who today have few treatment options. By reprogramming this innate system, we can harness the immense strength of our own bodies to target cancer in ways not possible before.
Our focus is on reprogramming immune cells to directly attack cancer as well as reduce suppression.
TARGETING THE TUMOUR MICROENVIRONMENT
Myeloid cells and cancer-associated fibroblasts are a major part of the tumour microenvironment.
THE FACTS
Cancer is on the rise. Research suggests we can expect over 29.5 million new cases of cancer by 2040.*
By targeting the immune system and not the cancer directly, our programs have the potential to treat several cancer types.
BREAST Cancer
316,950 estimated cases in the U.S. in 2025
Lung Cancer
226,650 estimated cases in the U.S. in 2025
COLORECTAL Cancer
154,270 estimated cases in the U.S. in 2025
Source: seer.cancer.gov
TECHNOLOGY
ME Therapeutics has two myeloid cell targeted drug development programs and one drug discovery program currently underway. All three programs target distinct areas of myeloid cell biology in order to inhibit the suppressive effects of suppressive myeloid cells on the anti-cancer immune response. These drug candidates are being developed to target pathways of myeloid cell biology that are not currently being targeted effectively.
Drug Development
Our two development programs include our anti-G-CSF antibody candidate (h1B11-12) and our myeloid targeted prodrug candidates (D094 and D099).
Drug DISCOVERY
Our drug discovery program is focussed on the discovery of novel lipid nanoparticle formulations capable of effectively delivering small molecule drugs and or nucleic acids to myeloid cells in tumors. This program will support our existing prodrug development as well as potentially provide therapies for targeting myeloid cells in IO.